Novo Nordisk A/S said it expects to start a cardiovascular outcomes trial for the diabetes drug Tresiba (insulin degludec) late this year in order to satisfy requirements by the US Food and Drug Administration which turned down the drug in February. ---Subscribe to MedNous to access this article--- Clinical Research Company News